Rob Scott Md Email and Phone Number
Los Angeles, CA, US
Rob Scott Md's Location
Los Angeles Metropolitan Area, United States, United States
Rob Scott Md's Contact Details
Rob Scott Md work email
- Valid
- Valid
- Valid
- Valid
Rob Scott Md personal email
n/a
Rob Scott Md phone numbers
About Rob Scott Md
Three decades in executive leadership positions in the Global Pharmaceutical Industry. Currently I am a Board member at seven companies, ranging from startup to publicly traded. I am a Strategic Advisory Board member at five companies, ranging amongst Biotech, Tech Companies, Venture Capital and Private Equity. Broad range of experience across the entire spectrum of drug discovery and development, strategic lifecycle planning and medical affairs in the world’s largest pharmaceutical company, the world's largest biotech company as well as emerging pharmaceutical and biotech companies. Thought Leader in the digitalization of Clinical Development through mobile health, Real World Data and Predictive Analytics.
Rob Scott Md's Current Company Details
Abionyx Pharma
View
Chief Medical Officer and Head of R and D
Los Angeles, CA, US
- Website:
- abionyx.com
- Employees:
- 9
Rob Scott Md Work Experience Details
-
Chief Medical Officer And Head Of R And DAbionyx PharmaLos Angeles, Ca, Us
-
Chief Medical Officer & Head Of R&DAbionyx Pharma Jan 2024 - PresentBalma, Occitanie, FrSepsis is one of the major medical challenges for new drug development. While Sepsis ranks third as a cause of death behind heart disease and cancer, those two diseases have been characterized by a huge amount of progress in terms of new therapies. This progress has led to steady reductions in age adjusted mortality over the last 20 years. There are no therapies that specifically target sepsis. While there have been advancements in understanding the pathophysiology of sepsis and developing novel therapeutic strategies, the translation of these approaches into approved therapies for sepsis has been unsuccessful. The treatment of sepsis is still limited to early recognition and diagnosis, prompt administration of antibiotics and supportive care measures such as fluid resuscitation, vasopressor therapy, and organ support in intensive care settings. These supportive therapies, while critical, have led to modest, incremental gains in mortality due to sepsis.At Abionyx, I hope to reverse this dismal record in sepsis with the help of forty years of research into the role that small discoidal HDL plays in applying breaks to the runaway inflammatory process that is the cause of mortality in sepsis and Abionyx recombinant, wild-type apoA-1.
-
Board MemberConfo Therapeutics 2020 - PresentZwijnaarde, BeConfo Therapeutics’ unparalleled technology stabilizes functional conformations of GPCRs (G protein-coupled receptors) to uncover a wide range of previously inaccessible GPCRs as drug targets.This technology platform combined with the pharmacologic and biologic insight it provides, allows Confo to build a multi-indication pipeline of drug candidates with the potential to transform therapeutic outcomes for patients with severe illnesses lacking disease-modifying treatments.Confo Therapeutics was spun out of Vrije Universiteit Brussel (VUB) and VIB in 2015. Supported by international life-science focused investors and led by an experienced team of entrepreneurial professionals and scientists from successful biopharmaceutical companies, Confo Therapeutics benefits from the rich scientific and innovative ecosystem in Belgium. Confo Therapeutics’ ability to access GPCR targets that have previously been difficult or even impossible to drug has already shown promise in producing exciting therapeutic candidate programs. -
Board MemberDraupnir Bio Sep 2020 - PresentCopenhagen, DkDraupnir Bio is harnessing the natural machinery of the lysosome to develop oral, small molecule degraders of extracellular pathogenic proteins – the next frontier of targeted protein degradation (TPD). We are extending the potential of protein degradation to target extracellular and membrane-bound proteins in a pioneering approach using our novel and differentiated, proprietary technology platform which targets lysosome receptors, and has the potential to revolutionize the field of TPD. Draupnir Bio is a spin out from Aarhus University and the Max-Planck Society based on the breakthrough scientific findings of Professors Simon Glerup, Camilla Gustafsen, Peder Søndergaard Madsen, and Peter Seeberger. -
Board MemberVariant Bio 2020 - PresentSeattle, Washington, UsHaving had the opportunity to successfully bring to market one therapeutic that emerged from rare genetic variants, Repatha, I am thrilled to work with the Variant Bio team and play a role in the novel science that is likely to emerge. My role was expanded this year to include both the Board and the Scientific Advisory Board and I'm looking forward to the increased perspective.Variant Bio is founded on a passion for exploration, and expertise spanning genetics, molecular biology, therapeutics, anthropology, and ethics. Variant Bio believes that human genomics has the power to transform drug development. Variant Bio combines anthropology, epidemiology, genetics, and machine learning to identify relevant people by focusing on outliers for traits of medical relevance and populations with rare genetic variants that rise to high frequency. Variant Bio uses innovative low- and high-pass whole-genome sequencing alongside custom algorithms to reduce costs without sacrificing data quality. Variant Bio has a unique approach powered by modern technology that brings communities, academia, healthcare providers, and the pharmaceutical industry under one roof to improve human health. An independent ethics advisory board, composed of indigenous community members, bioethicists, and genetic counselors, advises on every project. Variant prioritizes the needs and values of all their research partners and will protect the privacy and other rights of all participants, both individually and as a group. -
Board MemberOncospherix Jan 2021 - PresentOncoSpherix is the culmination of a multi-year research program to identify novel and clinically important aspects of the role of hypoxia-driven gene expression in tumor survival and spread, and to create and refine new chemical entities that target hypoxia-driven pathways. -
AdvisorBioethics International 2017 - PresentNew York, UsI am honored to work pro bono with Bioethics International (BEI) in their mission to advance patient and global public health by improving the ethics, transparency, patient-centricity, and governance of healthcare innovation and delivery. BEI focuses on the ethics and governance of how medicines, vaccines, biologics, and devices are researched, developed, marketed, and made accessible to patients domestically and globally. BEI focuses on the issues that matter to patients the most.For the last thirty years, my personal mission as a physician is to help patients by developing innovative new therapies for those in need. Unless we in Biopharma have the confidence of the public and potential subjects in our clinical trials that our primary concern is their safety, my mission becomes very difficult. Surveys suggest that we do not have that level of confidence that we should be striving for, even for the many companies that embrace the highest level of ethics and patient centricity. I believe that the BEI goal to increase transparency will force those companies that don't follow the highest ethical standards to raise the bar and will enhance the reputation of companies that are highly ethical. -
Board MemberRedx Pharma 2022 - Dec 2024Alderley Park, Macclesfield, GbRedx Pharma (AIM: REDX) is a clinical-stage biotechnology company focused on the discovery and development of novel, small molecule, highly targeted therapeutics for the treatment of cancer and fibrotic disease. Redx's lead oncology candidate, the Porcupine inhibitor RXC004, commenced a Phase 2 programme in November 2021. The Company's selective ROCK2 inhibitor candidate, RXC007, is in development for idiopathic pulmonary fibrosis and commenced a Phase 1 clinical trial in June 2021. -
Board MemberArisglobal 2020 - Oct 2024Waltham, Massachusetts, UsArisGlobal is transforming the way today’s most successful Life Sciences companies develop breakthroughs and bring new products to market. Our end-to-end drug development technology platform, LifeSphere®, integrates our proprietary Nava® cognitive computing engine to automate all core functions of the drug development lifecycle. Designed with deep expertise and a long-term perspective that spans more than 30 years, LifeSphere® boosts efficiency, ensures compliance, delivers actionable insights, and lowers total cost of ownership through multi-tenant Software-as-a-Service (SaaS) architecture. -
Board MemberWindtree Therapeutics, Inc. 2021 - Sep 2024Warrington, Pa, UsWindTree is a clinical-stage, biopharmaceutical and medical device company focused on the development of novel therapeutics intended to address significant unmet medical needs in important acute care markets. The lead development program, istaroxime, is a first-in-class treatment for acute heart failure and early cardiogenic shock and has Fast-Track designation. -
Strategic AdvisorMorningside Biopharma Advisory 2020 - Jun 2023
-
Chief Medical Officer, Head Of DevelopmentAbbvie Apr 2016 - May 2020North Chicago, Illinois, UsResponsible for leading AbbVie’s advancement of early and late stage development programs across a broad range of therapeutic areas (neuroscience, immunology, oncology, infectious disease, general medicine) including 10 late stage/phase 3 programs and over 20 early and mid-stage development projects.Manage an organization of over 3,300 individuals located in more than 50 countries and an external research spend of more than $1 billion.Board member of Transcelerate.Member of the PhRMA Biomedical Advisory Committee. -
Board MemberChicago Council On Science And Technology (C2St) Jan 2019 - Apr 2020Chicago, Il, Us -
R&D Leadership ForumPhrma Jun 2016 - Apr 2020Washington, District Of Columbia, UsI represented Abbvie at the R&D Leadership Forum, a group of Heads of R&D and Chief Medical Officers that replaced the Biomedical Advisory Committee (BMAC). -
Board MemberTranscelerate Biopharma Inc. May 2016 - Apr 2020Conshohocken, Pennsylvania, UsAs Chief Medical Officer and Head of Development, I represented Abbvie on the Transcelerate Board. -
Chairman Of The BoardKanan Therapeutics, Inc. Jan 2016 - Mar 2018Westlake Village, Ca, UsI was also a Founding Partner of Kanan which was established to do focused development on certain cardiovascular targets. -
Vice President, Global Development Ta Head, Head Development Design CenterAmgen Oct 2010 - Jan 2016Thousand Oaks, Ca, UsDuring the five years I worked at Amgen, I led the Cardiovascular, Metabolic, Nephrology, Neuroscience, Bone and Inflammation Therapeutic Areas. I also created a Center of Excellence for clinical trial design that utilized a suite of predictive analytic software and RWD to assist teams from all therapeutic areas with rational trial design and execution. As the global head of CV, Metabolism and Neuroscience Development I led the development of evolocumab (Repatha) which was the first PCSK9i to be filed and approved, the filing and apprval of ivabradine (Corlanor), which was approved by the FDA in 2015 for heart failure and omecamtiv mecarbil, a direct myosin activator that has just completed Phase 2 for heart failure. -
Committee MemberFda Jan 2012 - Dec 2015Silver Spring, Md, UsFDA's Advisory Committees have industry representatives who act on behalf of regulated industry at committee meetings. The representative discusses an issue before the committee from the perspective of the affected industry and not as an individual from a specific sponsor. Representatives are non-voting members who usually serve a four-year term. Selection is achieved by a process conducted by a committee of peers. While I was on the committee I participated in the following CRDAC meetings droxidopa, agalsidase alfa, rivaroxaban, lixavaptan, imatinib, riociguat, voroxapar, ticagrelor, serelaxin, nebivolol/valsartan and the Polypill. I have also substituted for the industry representative on the Endocine and Metabolic Drug Advisory Committe for insulin degludec and liraglutide. -
Chief Medical OfficerCerenis Therapeutics Jan 2008 - May 2010During my two and a half years at Cerenis, I had the opportunity to live and work in the south of France and experience the working environment in a highly innovative, pre-IPO company of less than thirty people. Cerenis Therapeutics is a pharmaceutical company focused on the discovery, development and commercialization of the next generation HDL therapies. As Chief Medical Officer with a staff of less than three, I rolled my sleeves up and did everything myself. Under my leadership, this micro team made significant progress on diverse programs with small molecules, peptides and engineered proteins. I designed and executed programs with synthetic HDL, PPAR delta, HDL mimetic peptides, and HDL enhancers.
-
Chief Medical Officer, Executive Vice President Of Research & DevelopmentAtherogenics Jul 2002 - Sep 2007UsI was Head of Research & Development at AtheroGenics and Executive Vice President. The Heads of Medicinal Chemistry, Biology, Animal Pharmacology, Early Development (including Toxicology and CMC), Clinical Development and Regulatory Affairs reported to me. I managed all aspects of Drug Development from synthesis and screening to Phase IV. The R&D group made up approximately eighty percent (around 135 individuals) of the total headcount of AtheroGenics. I also played a significant role supporting the financial group in raising capital, talking to key investors and financial analysts. -
Vice President Cardiovascular & Metabolic GroupPfizer 1992 - 2002New York, New York, UsAs the therapeutic head of the Cardiovascular & Metabolic group, I controlled the clinical and medical marketing support for 40% of the total Pfizer business. There were three Group Leaders reporting to me, Atherosclerosis (Lipitor, Caduet), Diabetes (Glucotrol XL and Exubera) and Cardiovascular (Norvasc, Accupril and Tikosyn). I managed a headcount of over 120 people in New York, Ann Arbor and Freiburg Germany. The group was responsible for a clinical trial program with over 120,000 patients participating in long term clinical studies and an annual budget of approximately US$200 million. -
Medical AdvisorJohnson & Johnson 1987 - 1989New Brunswick, Nj, UsAt Janssen, I set up and ran clinical programs on anesthetic agents (haloperidol, fentanyl, sufentanyl), anti-infectives (itraconazole), neuroleptics (ritanserin and risperidone), cardiovascular agents (nebivolol, ketanserin), antihelminthics, antihistamines and other agents. I also provided medical support for marketing in those areas where we had approved products (anesthetics, antifungals, antihistamines). This was a unique learning experience in a wide variety of therapeutic areas.While I was at Janssen, I was successful in setting up South Africa as the sixth largest contributor to Phase 1 through Phase 3 research within the global Janssen Research Foundation. These extensive research activities, funded from Belgium, created tremendous visibility and synergies for the local sales and marketing group with opinion leaders in South Africa.
Rob Scott Md Skills
Clinical Development
Pharmaceutical Industry
Clinical Trials
Drug Development
Biotechnology
Clinical Research
Regulatory Affairs
Drug Discovery
Medicine
Life Sciences
Diabetes
Fda
Commercialization
Strategy
Pharmacology
Biopharmaceuticals
Pharmaceutics
Medical Devices
Therapeutic Areas
Medical Affairs
R&d
U.s. Food And Drug Administration
Lifesciences
Cardiology
Oncology
Cro
Regulatory Submissions
Research And Development
Neuroscience
Cro Management
Rob Scott Md Education Details
-
University Of Cape TownMedicine -
University Of Cape TownMicrobiology And Biochemistry
Frequently Asked Questions about Rob Scott Md
What company does Rob Scott Md work for?
Rob Scott Md works for Abionyx Pharma
What is Rob Scott Md's role at the current company?
Rob Scott Md's current role is Chief Medical Officer and Head of R and D.
What is Rob Scott Md's email address?
Rob Scott Md's email address is ro****@****ott.org
What is Rob Scott Md's direct phone number?
Rob Scott Md's direct phone number is (847) 937*****
What schools did Rob Scott Md attend?
Rob Scott Md attended University Of Cape Town, University Of Cape Town.
What are some of Rob Scott Md's interests?
Rob Scott Md has interest in Sailing, Competitive Road Cycling.
What skills is Rob Scott Md known for?
Rob Scott Md has skills like Clinical Development, Pharmaceutical Industry, Clinical Trials, Drug Development, Biotechnology, Clinical Research, Regulatory Affairs, Drug Discovery, Medicine, Life Sciences, Diabetes, Fda.
Free Chrome Extension
Find emails, phones & company data instantly
Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Aero Online
Your AI prospecting assistant
Select data to include:
Total price:
$0.00
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial